Before the opening bell on Tuesday, Johnson & Johnson (JNJ
JNJ Earnings in Brief
Johnson & Johnson’s worldwide quarterly sales came in at $18.4 billion, up 6.3% from last year’s Q4 sales of $17.6 billion; however, due to negative currency impacts, the sales gain comes in at 4.5%. Excluding special items, JNJ’s net earnings for the quarter came in at $3.6 billion, or $1.24 per share, increasing from $3.4 billion, or $1.19 per share, in last year’s Q4. JNJ beat analysts’ estimates of $1.20 EPS on revenues of $17.95 billion. The company announced full year sales of $71.3 billion and EPS of $4.81, marking increases from last year’s full year results. Looking ahead to full year 2014, JNJ gave earnings estimates in the range of $5.75 to $5.85, which is on the low end of what analysts are looking for.CEO Commentary
Alex Gorsky, JNJ’s CEO and chairman, had the following to say about the company’s earnings report: ”Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business. We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence. I am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and consumers around the world.”
No Mention of Dividend
JNJ did not mention any dividend changes in its earnings report. The company most recently announced a dividend increase in April 2013, when it raised its dividend from 61 cents to 66 cents per quarter. The company will pay its next quarterly dividend on March 11, and the stock goes ex-dividend on February 21.
Stock Performance
JNJ’s stock was up 55 cents, or 0.58%, in pre-market trading. YTD, the company’s stock is up 4.43%.
No comments:
Post a Comment